At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 30 enrolled
Drug / intervention
Lasmiditandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Open Label Study to Compare the Bioavailability of Lasmiditan 200 mg Under Fed and Fasted Conditions in Healthy Male and Female Subjects
In Brief
A Phase 1 clinical trial evaluating Lasmiditan for Healthy. Completed, enrolled 30 participants.
Detailed Summary
This study will evaluate the effect of food on the pharmacokinetics (PK) of a single dose of lasmiditan in healthy participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
Countries--
CollaboratorsCoLucid Pharmaceuticals
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartJan 2015
Primary CompletionFeb 2015
Study CompletionMar 2015
TodayJul 2026
First PostedSep 8, 2014
Enrollment StartJan 1, 2015
Primary CompletionFeb 1, 2015
Study CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.8 years ago
Interventions
Lasmiditandrug
2 discrete doses separated by 6 days.